Thyrocare Technologies Ltd (THYROCARE) is currently trading at 488.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Thyrocare Technologies operates an affordable, technology-enabled diagnostic testing network serving patients, laboratories, hospitals, franchisees and healthcare partners across India, with an emerging international presence in Tanzania. Its core model combines automated laboratories, regional processing capacity, home collection, preventive testing and B2B distribution. The company delivered 25% consolidated revenue growth in Q2 FY27 and has sustained approximately 20% growth for nine consecutive quarters. Standalone revenue increased 26.7% to INR256 crore, while consolidated EBITDA rose 25%, demonstrating that rapid expansion has so far been accompanied by strong operating profitability. Franchise expansion is the primary growth engine: active franchisees reached 12,911 after approximately 1,180 additions in the quarter. Management expects annual additions of 1,500–2,000 over the medium term, potentially reaching 20,000–25,000 franchisees in five years, although new locations initially generate lower productivity than mature franchisees. Thyrocare is shifting from routine and preventive diagnostics toward specialty testing and consumer products. Allergy and reproductive genomics are commercially live, specialty contributes approximately 4% of pathology revenue today, and management targets 10–15% of revenue over three to five years; however, pregnancy-kit marketing investments will constrain near-term earnings accretion. The proposed exit from Nueclear Healthcare Limited is a major portfolio decision. Thyrocare is seeking shareholder approval to sell NHL for approximately INR141 crore, focusing capital and management attention on pathology, which has materially higher growth and ROCE than the radiology subsidiary.

Over the past 52 weeks, Thyrocare Technologies Ltd has traded between a low of ₹342.55 and a high of ₹662.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Thyrocare Technologies Ltd has a market capitalization of approximately 7,802.28. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Thyrocare Technologies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 54.45 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 7,802.28 Cr, Thyrocare Technologies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Thyrocare Technologies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Thyrocare Technologies Ltd is 54.45. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Thyrocare has begun specialty testing in reproductive genomics, with maternal screening as the initial focus. Management said the menu could move toward more detailed diagnosis related to that area, but did not list individual tests or prices.

Thyrocare operates 49 labs after Q2 FY27, comprising 48 in India and one in Tanzania. The network increased by five labs during the quarter and by 32 labs from the 17 reported in FY21.

Thyrocare said Nueclear Healthcare Limited, or NHL, had limited stand-alone growth prospects as a PET/CT operator in an integrated radiology market. Management cited an approximately 9% revenue decline over five quarters, 6.95% ROCE and equipment nearing the end of its life.

Thyrocare is selling its entire holding of 1,11,11,000 equity shares in Nueclear Healthcare. The shares represent 100% of Nueclear Healthcare's issued, subscribed and paid-up equity capital, including shares held through nominees.